In this work, we investigated the pharmacological effects of ICS-II on VSMC phenotypic transition and reveal the underlying mechanisms through in vivo and in vitro experiments. Our results highlight the thera-peutic benefits of ICS-II targeting VSMC phenotypic transition and sup-port the potential of pharmacological strategies in CVD management.